Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06678659 · ClinicalTrials.gov registry record · Phase 1
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
A Phase 1 study of Locally Advanced and Unresectable, sponsored by Recursion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 6
- Study locations
NCT06678659: Recruiting Phase 1 study of Locally Advanced and Unresectable, sponsored by Recursion Pharmaceuticals.
NCT06678659 is a Phase 1 study of Locally Advanced and Unresectable that is actively recruiting participants, run by Recursion Pharmaceuticals. The registered enrollment target is 85 participants, below the 163-participant average among 6 other Locally Advanced trials with a reported enrollment target (48% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06678659, a Phase 1 study of Locally Advanced and Unresectable, is actively recruiting participants, sponsored by Recursion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Primary Outcome
To characterize the incidence of DLTs
Conditions Studied
Interventions
- DRUG REC-1245
Study Locations (6)
California
- City of Hope - Duarte
Ohio
- Cleveland Clinic - Cleveland
Tennessee
- SCRI Oncology Partners - PPDS - Nashville
Utah
- START Mountain Region - West Valley City
Canada
- McGill University Health Centre (MUHC) - The Montreal - Québec
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
What NCT06678659 shows while recruiting
NCT06678659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 163-participant average among 6 other Locally Advanced trials with a reported enrollment target (48% lower).
The record links to 4 conditions, with Locally Advanced appearing as the primary indexed condition, and to 1 intervention - of which REC-1245 is the first listed.
NCT06678659 lists 6 locations in 6 states (California, Ohio, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06678659 about?
NCT06678659 is a clinical study titled "A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer". This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
What is the current status of trial NCT06678659?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2024-11-21. Estimated completion is 2028-10-30.
What conditions does trial NCT06678659 study?
This clinical trial studies the following conditions: Locally Advanced, Unresectable, Metastatic Cancers, Relapsed/Refractory Lymphomas.
What interventions are being tested in trial NCT06678659?
The interventions under investigation include: REC-1245 (DRUG).
Who is sponsoring clinical trial NCT06678659?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06678659 being conducted?
This trial has 6 study locations across California, Ohio, Tennessee, Utah, Canada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RECRUITING · Phase 1
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
RECRUITING · Phase 2
-
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
RECRUITING · NA
-
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI